[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591582":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":23,"locations":32,"responsibleParty":50,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[68Ga]Ga-DOTA-TOC PET imaging","EXPERIMENTAL",null,[13],"Other: [68Ga]Ga-DOTA-TOC PET imaging",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":11},"Patients will undergo \\[68Ga\\]Ga-DOTA-TOC PET imaging before and 3 weeks after start of standard of care treatment with induction chemotherapy or CRT, unless the baseline scan shows no tracer uptake in the tumor, in that case the scan will not be repeated.\n\nPatients will receive 120 MBq \\[68Ga\\]Ga-DOTA-TOC intravenously and will be scanned up to 20 minutes, 60 minutes after tracer injection, after acquisition of a low dose CT for attenuation correction.\n\nThe investigators will use archival tissue of the diagnostic biopsy for SSTR2 staining. If there is not sufficient tumor tissue available, a new biopsy will be performed after the baseline PET scan.\n\nBlood samples will be drawn before the start, during and after finishing therapy at 3 or 4 different time points, depending on the treatment schedule.",[9],[19],{"name":20,"affiliation":21,"role":22},"Sjoukje F. Oosting, MD, PhD","University Medical Center Groningen, Dept. of Medical Oncology, Hanzeplein 1, 9713 GZ Groningen, The Netherlands","PRINCIPAL_INVESTIGATOR",[24,28],{"name":20,"role":25,"phone":26,"phoneExt":11,"email":27},"CONTACT","+31 50 3612821","s.oosting@umcg.nl",{"name":29,"role":25,"phone":30,"phoneExt":11,"email":31},"Fleur van Doorn, MD","+31 50 361 2821","f.l.van.doorn@umcg.nl",[33],{"facility":5,"status":34,"city":35,"state":11,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Groningen","9713 GZ","Netherlands","NL",{"type":40,"coordinates":41},"Point",[42,43],6.56667,53.21917,{"lat":43,"lon":42},[46,47,48],{"name":20,"role":25,"phone":30,"phoneExt":11,"email":27},{"name":29,"role":25,"phone":30,"phoneExt":11,"email":31},{"name":49,"role":22,"phone":11,"phoneExt":11,"email":11},"Sjoukje F. Oosting",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100591582","phase-1-sstr2-imaging-with-68gaga-dota-toc-petct-in-npc-100591582",false,"NCT06982300","SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET\u002FCT in NPC","Towards Improved Therapy Selection and Targeted Treatment for Nasopharyngeal Carcinoma: a Proof-of-concept Pilot Study for Somatostatin Receptor 2 Imaging With [68Ga]Ga-DOTA-TOC PET\u002FCT.","NACASOR","Inclusion Criteria:\n\n* Stage IB-IVA NPC (AJCC 9th edition), EBV positive determined by Epstein-Barr virus-encoded RNA (EBER).\n* Planned treatment with induction chemotherapy or CRT without induction chemotherapy.\n* Age ≥ 18 years.\n* Signed informed consent.\n* Willingness and ability to comply with all protocol required procedures.\n* Negative serum pregnancy test at screening in women of childbearing potential.\n* Archival tumor tissue available or consent to undergo a tumor biopsy procedure.\n\nExclusion Criteria:\n\n* Previous treatment with chemotherapy or radiotherapy for NPC.\n* Treatment with any investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to \\[68Ga\\]Ga-DOTA-TOC injection.\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or that may affect the interpretation of the results or render the patient at high risk from complications.\n* Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n* Inability to lie in supine position for 25 minutes.\n* Patients who are pregnant or breastfeeding.","ALL","18 Years",{"count":63,"type":64},10,"ESTIMATED","INTERVENTIONAL",[67,68],"PHASE1","PHASE2","This is an investigator-initiated, single-center clinical trial designed to evaluate the feasibility of \\[68Ga\\]Ga-DOTA-TOC positron emission tomography (PET) scan in patients with Epstein-Barr virus (EBV) related nasopharyngeal carcinome (NPC) prior to and three weeks after the start of induction chemotherapy or concurrent chemoradiotherapy (CRT). Archival tumor tissue from the diagnostic biopsy will be used to perform somatostatin receptor 2 (SSTR2) immunohistochemistry (IHC). Blood samples will be drawn at baseline, after three weeks, after completion of induction chemotherapy if applicable, and after CRT.",[71],"Nasopharyngeal Carcinoma (NPC)","2025-09-29",{"date":74,"type":75},"2025-10-03","ACTUAL",{"date":77,"type":75},"2025-09-25",{"date":79,"type":64},"2026-12",{"name":5,"class":6},1]